BONTRIL Drug Patent Profile
✉ Email this page to a colleague
When do Bontril patents expire, and when can generic versions of Bontril launch?
Bontril is a drug marketed by Valeant and Bausch and is included in two NDAs.
The generic ingredient in BONTRIL is phendimetrazine tartrate. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bontril
A generic version of BONTRIL was approved as phendimetrazine tartrate by CHARTWELL on October 30th, 1991.
US Patents and Regulatory Information for BONTRIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant | BONTRIL | phendimetrazine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 088021-001 | Sep 21, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bausch | BONTRIL PDM | phendimetrazine tartrate | TABLET;ORAL | 085272-001 | Approved Prior to Jan 1, 1982 | AA | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
